Management of Cardiac Involvement in NeuroMuscular Diseases: Review
Rachida Bouhouch*, Tarik Elhouari, Latifa Oukerraj, Ibtissam Fellat, Jamila Zarzur, Rajaa Bennani, Mhamed Arharbi
Identifiers and Pagination:Year: 2008
First Page: 93
Last Page: 96
Publisher ID: TOCMJ-2-93
Article History:Received Date: 10/9/2008
Revision Received Date: 24/9/2008
Acceptance Date: 26/9/2008
Electronic publication date: 22/10/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Neuromuscular Diseases are a heterogeneous molecular, clinical and prognosis group. Progress has been achieved in the understanding and classification of these diseases.
Cardiac involvement in neuromuscular diseases namely conduction disorders, ventricular dilatation and dilated cardiomyopathy with its impact on prognosis, is often dissociated from the peripheral myopathy. Therefore, close surveillance is mandatory in the affected patients. In this context, preventive therapy (beta-blockers and angiotensin converting enzyme inhibitors) has been recently recommended in the most common Neuromuscular Diseases, Duchenne Muscular Dystrophy and Myotonic Dystrophy.